Alteration of intracellular Ca2+-handling and receptor regulation in hypertensive cardiac hypertrophy: Insights from Ren2-transgenic rats

Cardiovascular Research

Volumn 39, Issue 1, 1998, Pages 242-256

  Zolk, Oliver ^a   Flesch, Markus ^a   Nickenig, Georg ^a   Schnabel, Petra ^a   Böhm, Michael ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Adrenergic signal transduction; Ca2+ handling proteins; Cardiac hypertrophy; Heart failure; Renin angiotensin system; TG(mREN2)27 rat

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ADRENERGIC RECEPTOR; CALCIUM; RENIN;

ADRENERGIC SYSTEM; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE PRESSURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; ANIMAL; CARDIOMEGALY; GENETICS; HEART CONTRACTION; HOMEOSTASIS; HUMAN; HYPERTENSION; INTRACELLULAR FLUID; METABOLISM; PHYSIOLOGY; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CALCIUM; CARDIOMEGALY; HOMEOSTASIS; HUMANS; HYPERTENSION; INTRACELLULAR FLUID; MYOCARDIAL CONTRACTION; RATS; RECEPTORS, ADRENERGIC; RENIN; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 0032105499     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00081-9     Document Type: Article

References (144)

1. [1] Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of the congestive heart failure. The Framingham study . New Engl J Med 1972;287:781-787.
2. [2] Samani NJ, Swales JD, Brammar WJA. Widespread abnormality of renin gene expression in the spontaneously hypertensive rat: modulation in some tissues with the development of hypertension. Clin Sci 1989;77:629-636.
3. [3] Castellano M, Böhm M. The cardiac β-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. Hypertension 1997;29:715-722.
4. [4] Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-254.
5. [5] Paul M, Stock P, Langheinrich M, Liefeldt L, Schönfelder G, Böhm M. Role of the cardiac renin-angiotensin system in human heart failure. Adv Exp Med Biol 1995;377:279-283.
6. [6] Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. J Clin Invest 1990;86:1913-1920.
7. [7] Bristow MR, Anderson FL, Port JD, et al. Differences in β-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:1024-1039.
8. [8] Böhm M, Gräbel C, Knorr A, Erdmann E. Treatment in hypertensive cardiac hypertrophy I. Neuropeptide Y and β-adrenoceptors. Hypertension 1995;25:954-961.
9. [9] Esler MG, Masking GJ, Wilet IR, Leonard PK, Jennings GL. Noradrenaline release and sympathetic nervous system activity. J Hypertens 1988;3:117-119.
10. [10] Laragh JH, Sealey JE. The renin-angiotensin-aldosterone system in hypertension disorders: a key to two forms of arteriolar vasoconstriction and a positive clue to risk of vascular injury (heart attack and stroke) and prognosis. In: Laragh JH, Brenner BM, editors. Hypertension: Pathophysiology, Diagnosis and Management. New York: Raven Press, 1990:1329-1348.
11. [11] Weber KT, Brilla CG. Factors associated with reactive and reparative fibrosis of the myocardium. Basic Res Cardiol 1992;87(suppl 7):291-301.
12. [12] Simpson P. Norepinephrine stimulated hypertrophy of cultured rat myocardial cells is an α1-adrenergic response. J Clin Invest 1983;72:732-738.
13. [13] Schwartz K, de la Bastie D, Bouveret P, Oliviero P, Alonso S, Buckingham ME. α-Skeletal muscle actin mRNAs accumulate in hypertrophied adult rat hearts. Circ Res 1986;59:551-555.
14. [14] Waspe LE, Ordahl CP, Simpson PC. The cardiac β-myosin heavy chain isogene is induced selectively in α1-adrenergic receptor stimulated hypertrophy of cultured rat heart myocytes. J Clin Invest 1990;85:1206-1214.
15. [15] Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of β-adrenergic receptor function. FASEB J 1990;4:2881-2889.
16. [16] Wankerl M, Schwartz K. Calcium transport proteins in the nonfailing and failing heart: gene expression and function. J Mol Med 1995;73:487-496.
17. [17] del Monte F, Harding SE, Rosano GMC, Poole-Wilson PA. Contractile properties of hypertrophic and non hypertrophic human ventricular myocytes in patients with ischemic cardiomyopathy. Circulation 1992;86:426-430.
18. [18] Beuckelmann DJ, Näbauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992;85:1046-1055.
19. [19] Böhm M, Gierschik P, Larisch K, Weismann K, Erdmann E. Role of altered G-protein expression in the regulation of myocardial adenylate cyclase activity and force of contraction in spontaneous hypertensive cardiomyopathy in rats. J Hypertens 1992;10:1115-1128.
20. [20] Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990;344:541-544.
21. [21] Lee MA, Böhm M, Kim S, et al. Differential gene expression of renin and angiotensinogen in the TGR(mREN2)27 transgenic rat. Hypertension 1995;25:570-580.
22. [22] Zolk O, Flesch M, Schnabel P, et al. Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and β-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats. Br J Pharmacol 1998;132:405-412.
23. [23] Bader M, Zhao Y, Sander M, et al. Role of tissue renin in the pathophysiology of hypertension in TG(mREN2)27 rats. Hypertension 1992;19:681-686.
24. [24] Flesch M, Schiffer F, Zolk O, Pinto Y, Paul M, Böhm M. Contractile diastolic and systolic dysfunction is accompanied by an altered sarcoplasmic reticulum gene expression and a myosin isoform shift in renin-induced hypertensive cardiomyopathy. Hypertension 1997;30:383-391.
25. [25] Lee MA, Böhm M, Paul M, Bader M, Ganten U, Ganten D. Physiological characterization of the hypertensive transgenic rat TGR(mREN2)27. Am J Physiol 1996;270:E919-E929.
26. [26] Ganten D, Lindpaintner K, Ganten U, et al. Transgenic rats: new animal models in hypertension research. Hypertension 1991;17:843-855.
27. [27] Hilgers KF, Peters J, Veelken R, et al. Increased vascular angiotensin formation in female rats harboring the mouse REN-2 gene. Hypertension 1992;19:687-691.
28. [28] Pinto YM, Buikema H, van Gilst WH, et al. Cardiovascular end-organ damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats. J Mol Med 1997;75:371-377.
29. [29] Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993;45:205-251.
30. [30] Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2 receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-657.
31. [31] Booz GW, Baker KM. Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension 1996;28:635-640.
32. [32] Hain L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. Behavioral and cardiovascular effects of disrupting the angiotensin II type 2 receptor in mice. Nature 1995;377:744-747.
33. [33] Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 1996;93:156-160.
34. [34] Haywood GA, Gullestad L, Katsuya T, Hutchinson HG, Pratt RE, Horiuchi M, Fowler MB. AT1 and AT2 angiotensin receptor gene expression in human heart failure. Circulation 1997;95:1201-1206.
35. [35] Asano K, Dutcher DL, Port JD, et al. Selective downregulation of the angiotensin II AT1 receptor subtype in failing ventricular myocardium. Circulation 1997;95:1193-1200.
36. [36] Lopez JJ, Lorell BH, Ingelfinger JR, Weinberg EO, Schunkert H, Diamant D, Tang SS. Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol 1994;267:H844-H852.
37. [37] Moravec SJ, Schluchter MD, Paranandi L, Czerska B, Stewart RW, Rosenkranz E, Bond M. Inotropic effects of angiotensin II on human cardiac muscle in vitro. Circulation 1990;82:1973-1984.
38. [38] Ishihata A, Endoh M. Species-related differences in inotropic effects on angiotensin II in mammalian ventricular muscle: receptors, subtypes and phosphoinositide hydrolysis. Br J Pharmacol 1995;114:447-453.
39. [39] Lenz O, Schmid B, Kilter H, et al. Effects of angiotensin II and angiotensin converting enzyme inhibitors on human myocardium. Eur, J Pharmacol 1995;249:17-27.
40. [40] Rosenkranz S, Nickenig G, Flesch M, Cremers B, Schnabel P, Lenz O, Krause T, Ganten D, Hoffmann S, Böhm M. Cardiac angiotensin II receptors: studies on functional coupling in Sprague-Dawley rats and TGR(αMHC-hAT1) transgenic rats. Eur J Pharmacol 1997;330:35-46.
41. [41] Holubarsch C, Hasenfuss G, Schmidt-Schweda S, Knorr A, Pieske B, Ruf T, Fasol R, Just H. Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium. Circulation 1993;88:1228-1234.
42. [42] Nickenig G, Laufs U, Schnabel P, Knorr A, Paul M, Böhm M. Down-regulation of aortic and cardiac AT1 receptor gene expression in transgenic (mREN-2)27 rats. Br J Pharmacol 1997;121:134-140.
43. [43] Nosek TM, Williams MF, Zeigler ST, Godt RE. Inositol triphosphate enhances calcium release in skinned cardiac and skeletal muscle. Am J Physiol 1111;250:C807-C811.
44. [44] Ikenouchi H, Barry WH, Bridge JHB, Weinberg EO, Apstein CS, Lorell BH. Effects of angiotensin II on intracellular Ca2+ and pH in isolated beating rabbit hearts and myocytes loaded with the indicator indo-1. J Physiol 1994;480:203-215.
45. [45] Leatherman GF, Kim D, Smith TW Effect of phorbol esters on contractile state and calcium flux in cultured chick heart cells. Am J Physiol 1987;252:H205-H209.
46. [46] Gwathmay JK, Harjjar RJ. Effect of protein kinase C activation on sarcoplasmic reticulum function and apparent myofibrillar Ca2+ sensitivity in intact and skinned muscles from normal and diseased myocardium. Circ Res 1990;67:744-752.
47. [47] Lorell BH. Diastolic dysfunction in pressure-overload hypertrophy and its modification by angiotensin II: current concepts. Basic Res Cardiol 1992;87(Suppl. 2):163-172.
48. [48] Pucéat M, Vassort G. Neurohumoral modulation of intracellular pH in the heart. Cardiovasc Res 1995;29:178-183.
49. [49] Mancia G, Saino A, Grassi G, 1995. Interactions between the sympathetic nervous system and the renin angiotensin system. In: Laragh JH, Brenner BM, editors. Hypertension: Pathophysiology, Diagnosis and Management, Please supply publisher, pp. 399-407.
50. [50] Reit E. Actions of angiotensin on the adrenal medulla and autonomic ganglia. Fed Proc 1972;31:1338-1343.
51. [51] Farr WC, Grupp G. Ganglionic stimulation: mechanisms of the positive inotropic and chronotropic effects of angiotensin. J Pharmacol Exp Ther 1971;177:48-55.
52. [52] Majewski H, Hedler L, Schnurr C, Starke K. Modulation of noradrenaline release in the pithed rabbit: a role for angiotensin II. J Cardiovasc Pharmacol 1984;6:888-889.
53. [53] Malik KU, Nasjletti A. Facilitation of adrenergic transmission by locally generated angiotensin II in rat mensenteric arteries. Circ Res 1976;38:26-30.
54. [54] Ferrario CM, Gildenberg PL, McCubbin JW. Cardiovascular effects of angiotensin mediated by the central nervous system. Circ Res 1972;30:257-262.
55. [55] Reid IA. Actions of angiotensin II on the brain: mechanisms and physiologic role. Am J Physiol 1984;246:F533-F543.
56. [56] Haass M, Cheng B, Richardt G, Lang RE, Schömig A. Characterization and presynaptic modulation of stimulation-evoked exocytotic co-release of noradrenaline and neuropeptide Y in guinea pig heart. Naunyn-Schmiedeberg's Arch Pharmacol 1989;339:71-78.
57. [57] Packer M. Neurohormonal interactions and adaptions in congestive heart failure. Circulation 1988;77:721-730.
58. [58] Böhm M, La Rosée K, Schwinger RHG, Erdmann E. Evidence for a reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 1995;25:148-153.
59. [59] Benedict CR, Shelton B, Johnstone DE, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996;94:690-697.
60. [60] Daly PA, Sole MJ. Myocardial catecholamines and the pathophysiology of heart failure. Circulation 1990;82(Suppl I):I35.
61. [61] Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990;82:1724-1729.
62. [62] Goldstein DS. Plasma catecholamines and essential hypertension. Hypertension 1983;5:86-99.
63. [63] Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac sympathetic activation in human heart failure. Circulation 1997;95:169-175.
64. [64] Zerkowski H-R, Broede A, Kunde K, et al. Comparison of the positive inotropic effects of serotonin, histamine, angiotensin II, endothelin and isoprenaline in the isolated human right atrium. Naunyn-Schmiedeberg's Arch Pharmacol 1993;347:347-352.
65. [65] Yatani A, Brown AM. Rapid β-adrenergic modulation of cardiac calcium channel currents by a fast G-protein pathway. Science 1989;245:71-74.
66. [66] Yanagisawa T, Ishii K, Hashimoto H, Taira N. Differential coupling to positive inotropic responses of cyclic AMP produced by stimulation of beta 1- and beta 2-adrenergic receptors. J Cardiovasc Pharmacol 1989;13:64-75.
67. [67] Xiao RP, Hohl C, Altschuld R, et al. β2-Adrenergic receptor-stimulated increase in cAMP in rat heart cells is not coupled to changes in Ca2+ dynamics, contractility, or phospholamban phosphorylation. J Biol Chem 1994;269:19151-19156.
68. [68] Kaumann AJ, Lemoine H. β2-Adrenoceptor-mediated positive inotropic effect in human ventricular myocardium. Quantitative discrepancies with binding and adenylate cyclase stimulation. Naunyn Schmiedeberg's Arch Pharmacol 1987;335:403-411.
69. [69] Borea PA, Amerini S, Masini I, et al. Beta 1- and beta 2-adrenoceptors in sheep cardiac ventricular muscle. J Mol Cell Cardiol 1992;24:753-763.
70. [70] Rohrer DK, Desai KH, Jasper JR, et al. Targeted disruption of the mouse β1-adrenergic receptor gene: developmental and cardiovascular effects. Proc Natl Acad Sci USA 1996;93:7375-7380.
71. [71] Böhm H, Zolk O, Flesch M, Schiffer F, Schnabel P, Stasch J-P, Knorr A. Effects of angiotensin II type 1 receptor blockade and angiotensin-converting enzyme inhibition on cardiac β-adrenergic signal transduction. Hypertension 1989;31:747-754.
72. [72] Müller FU, Boheler KR, Eschenhagen T, Schmitz W, Scholz H. Isoprenaline stimulates gene transcription of the inhibitory, G-protein alpha-subunit Gi-alpha-2 in rat heart. Circ Res 1993;72:696-700.
73. [73] Böhm B, Gierschik P, Jakobs KH, et al. Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy. Circulation 1990;82:1249-1265.
74. [74] Weinstein LS, Spiegel AM, Carter AD. Cloning and characterization of the human gene for the alpha subunit of Gi2, a GTP binding signal protein. FEBS Lett 1988;232:333-340.
75. [75] Böhm M, Moll M, Schmid B, et al. β-Adrenergic neuroeffector mechanism in cardiac hypertrophy of renin transgenic rats. Hypertension 1994;24:653-662.
76. [76] Böhm M, Gierschik P, Knorr A, Schmidt U, Weismann K, Erdmann E. Desensitization of adenylate cyclase and increase of Giαa in cardiac hypertrophy due to acquired hypertension. Hypertension 1992;20:103-112.
77. [77] Böhm M, Gierschik P, Knorr A, Schmidt U, Weismann K, Erdmann E. Myocardial adenylyl cyclase, β-adrenoceptors, and G-proteins in salt-sensitive hypertension. Hypertension 1993;22:715-727.
78. [78] Böhm M. Alterations of β-adrenoceptor-G-protein-regulated adenylyl cyclase in heart failure. Mol Cell Biochem 1995;147:147-160.
79. [79] Böhm M, Kirchmayr R, Erdmann E. Myocardial Gi alpha protein levels in patients with hypertensive cardiac hypertrophy, ischemic heart disease and cardiogenic shock. Cardiovasc Res 1995;30:611-618.
80. [80] Schmitz W, Scholz H, Scholz J, Steinfath M. Increase in IP3 precedes alpha-adrenoceptor-induced increase in force of contraction in cardiac muscle. Eur J Pharmacol 1987;140:109-111.
81. [81] Skomedal T, Schiander I, Osnes J-B. Both α- and β-adrenoceptor mediated components contribute to final inotropic response to norepinephrine in rat hearts. J Pharmacol Exp Ther 1988;247:1204-1210.
82. [82] Brückner T, Scholz H. Effects of α-adrenoceptor stimulation with phenylephrine in the presence of propranolol on force of contraction, slow inward current and cyclic AMP content in the bovine heart. Br J Pharmacol 1984;82:223-233.
83. [83] Schnabel P, Gäs H, Nohr T, Camps M, Böhm M. Identification and characterization of G-protein regulated phospholipase C in human myocardium. J Mol Cell Cardiol 1996;28:2419-2427.
84. [84] Apkon M, Nerbonne JM. α1-adrenergic agonisls selectively suppress voltage-dependent K+ currents in rat ventricular myocytes. Proc Natl Acad Sci USA 1988;85:8756-8760.
85. [85] Fedida D, Bouchard RA. Mechanisms for the positive inotropic effect of α1-adrenoceptor stimulation in rat cardiac myocytes. Circ Res 1992;71:673-688.
86. [86] Gambassi G, Spurgeon HA, Lakatta EG, Blank PS, Capogrossi MC. Different effects of α- and β-adrenergic stimulation on cytosolic pH. and myofilament responsiveness to Ca2+ in cardiac myocytes. Circ Res 1992;71:870-882.
87. [87] Buxton I, Brunton L. α-Adrenergic receptors on rat ventricular myocyles: characteristics and linkage to cAMP melabolism. Am J Physiol 1997;251:H307-H313.
88. [88] Kentish JC, Barsolli RJ, Lea TJ, Mulligan IP, Palel JR, Ferenczi MA. Calcium release from cardiac sarcoplasmic reticulum induced by photo release of calcium or Ins (1,4,5)P3. Am J Physiol 1990;258:H610-H615.
89. [89] Hansen CA, Joseph SK, Robishaw JD. Ins 1,4,5-P3 and Ca2+ signaling in quiescent neonatal cardiac myocytes. Biochim Biophys Acta 1994;1224:517-526.
90. [90] Woodcock EA. Inositol phosphates in the heart: controversy and consensus. J Mol Med 1995;73:313-323.
91. [91] Bevilacqua M, Vago T, Norbiato G, et al. Characterization of alphal-adrenergic receptors in the sacolemma from the myocardium of patients with dilated cardiomyopathy. J Cardiovasc Pharmacol 1987;19(Suppl 4):S94-S96.
92. [92] Bristow MR, Minobe W, Rasmussen R, Hershberger RE, Hoffman BR. Alpha1 adrenergic receptors in the nonfailing and failing human heart. J Pharmacol Exp Ther 1988;247:1039-1045.
93. [93] Schmitz W, Scholz H, Erdmann E. Effects of alpha- and beta-adrenergic agonists, phosphodiesterase inhibitors and adenosine on isolated human heart muscle preparation. Trends Pharm Sci 1987;8:447-450.
94. [94] Böhm M, Diet F, Feiler G, Kemkes K, Erdmann E. Alpha-adrenoceptors and alpha-adrenoceptor mediated positive inotropic effects in failing human myocardium. J Cardiovasc Pharmacol 1988;12:357-364.
95. [95] Schnabel P, Nohr T, Nickenig G, Paul M, Böhm M. Alpha-adrenergic signal transduction in renin transgenic rats. Hypertension 1997;30:1356-1361.
96. [96] Luo W, Grupp WL, Harrer J, et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ Res 1994;75:401-409.
97. [97] Kadambi VJ, Ponniah S, Harrer JM, et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanisms in transgenic mice. J Clin Invest 1996;97:533-539.
98. [98] Luo W, Wolska BM, Grupp IL, et al. Phospholamban gene dosage effects in the mammalian heart. Circ Res 1996;78:839-847.
99. [99] Lamers JHJ, Stinis JT. Defective calcium pump in the sarcoplasmic reticulum of the hypertrophied rabbit heart. Life Sci 1979;24:2313-2320.
100. [100] de la Bastie D, Levitsky D, Rappaport L, et al. Function of the sarcoplasmic reticulum and of its Ca2+-ATPase gene in pressure overload-induced cardiac hypertrophy in the rat. Circ Res 1990;66:554-564.
101. [101] Flesch M, Schwinger RH, Schnabel P, et al. Sarcoplasmic reticulum Ca2+-ATPase and phospholamban mRNA and protein levels in end stage heart failure due to ischemic or dilated cardiomyopathy. J Mol Med 1996;74:321-332.
102. [102] Schwinger RH, Böhm M, Schmidt U. Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca2+-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 1995;92:3220-3228.
103. [103] Mercadier JJ, Lompré AM, Duc P, et al. Altered sarcoplasmic reticulum Ca2+-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest 1990;85:305-309.
104. [104] Meyer M, Schillinger W, Pieske B, et al. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 1995;92:778-784.
105. [105] Darvish A, Schomisch-Moravec SC. Decreased sarcoplasmic reticulum content in the failing human heart is associated with a decrease in the Ca2+ ATPase and phospholamban proteins. (Abstract). Circulation 1994;90:I217.
106. [106] Movsesian MA, Bristow MR, Krall J. Ca2+ uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy. Circ Res 1989;65:1141-1144.
107. [107] Flesch M, Pinto Y, Schiffer F, et al. Angiotensin receptor antagonism and ACE-inhibition equally improve diastolic dysfunction and SR Ca2+-ATPase expression in hypertensive cardiomyopathy. J Hypertens 1997;15:1001-1009.
108. [108] Kagaya J, Hajjar RJ, Gwethmey JK, Barry WH, Lorell BH. Long-term angiotensin-converting enzyme inhibition with fosinopril improves depressed responsiveness to Ca2+ in myocytes from aortic-banded rats. Circulation 1996;94:2915-2922.
109. [109] Holtz J, Studer R, Reinecke H, Drexler H. Modulation of myocardial sarcoplasmic reticulum Ca2+ ATPase in cardiac hypertrophy by angiotensin converting enzyme?. Basic Res Cardiol 1992;87(Suppl 2):191-204.
110. [110] Reinicke H, Studer R, Zierhut W, Drexler H. Downregulation of sarcoplasmic reticulum (SR) Ca2+ ATPase mRNA by angiotensin II in adult rat cardiomyocytes (Abstract). Circulation 1995;92:I283.
111. [111] Ikeda U, Tsuruya Y, Yaginuma T. α1-Adrenergic stimulation is coupled to cardiac myocyte hypertrophy. Am J Physiol 1991;260:H953-H956.
112. [112] Schlüter KD, Millar BC, McDermott BJ, Piper HM. Regulation of protein synthesis and degradation in adult ventricular cardiomyocytes. Am J Physiol 1995;269:C1347-C1355.
113. [113] Long CS, Hartogenesis WE, Simpson PC. β-Adrenergic stimulation of cardiac non-myocytes augments the growth promoting activity of non-myocyte conditioned medium. J Mol Cell Cardiol 1993;25:915-925.
114. [114] Boheler KR, Schwartz K. Gene expression in cardiac hypertrophy. Trends Cardiovasc Med 1992;2:176-182.
115. [115] Waspe LE, Ordahl CP, Simpson PC. The cardiac β-myosin heavy chain isogene is induced selectivly in α1-adrenergic receptor-stimulated hypertrophy of cultured rat heart myocytes. J Clin Invest 1990;85:1206-1214.
116. [116] Schwartz K, Boheler KR, de la Bastie D, Lompre AM, Mercadier JJ. Switches in cardiac muscle gene expression as a result of pressure and volume overload. Am J Physiol 1992;262:R364-R369.
117. [117] Ohta K, Kim S, Wanibuchi H, Ganten D, Iwao H. Contribution of local renin-angiotensin system to cardiac hypertrophy, phenotypic modulation, and remodeling in TGR(mREN2)27 transgenic rats. Circulation 1996;94:785-791.
118. [118] Dostal DE, Baker KM. Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Am J Hypertens 1992;5:276-280.
119. [119] Sadoshima J, Xu F, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac muscle in vitro. Cell 1993;75:977-984.
120. [120] Sadoshima J, Izumo S. Molecular characterization of angiotensin II induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Circ Res 1993;87:921-930.
121. [121] Pönicke K, Heinroth-Hoffmann I, Becker K, Brodde O-E. Trophic effect of angiotensin II in neonatal rat cardiomyocytes: role of endothelin-1 and non-myocyte cells. Br J Pharmacol 1997;121:118-124.
122. [122] Sadochima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 1993;75:977-984.
123. [123] Sadochima J, Lahn L, Takahashi T, Kulik TJ, Izumo S. Molecular characterization of the stretch-induced adaptation of cultured cardiac cells: an in vitro model of load-induced cardiac hypertrophy. J Biol Chem 1992;267:10551-10560.
124. [124] Böhm M, Lippoldt A, Wienen W, Ganten D, Bader M. Reduction of cardiac hypertrophy in TG(mREN2)27 by angiotensin II receptor blockade. Mol Cell Biochem 1996;163/164:217-221.
125. [125] Linz W, Henning R, Schölkens BA. Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy. J Hypertens 1991;9(suppl 6):S400-S401.
126. [126] Ruzicka M, Yuan B, Harmsen E, Leenen FHH. The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effect of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker. Circulation 1993;87:927-930.
127. [127] Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein C, Lorell B. Increased rat angiotensin converting enzyme activity and mRNA-levels in pressure overload left ventricular hypertrophy: effects on coronary resistance, contractility and relaxation. J Clin Invest 1990;86:535-539.
128. [128] Cachefeiro V, Sakskibara T, Nasjletti A. Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension 1992;19:138-145.
129. [129] Swartz SL, Williams GH, Hollenberg NK. Captopril induced changes in prostaglandin production. J Clin Invest 1980;65:1257-1264.
130. [130] Urata H, Nishimura H, Ganten D. Mechanisms of angiotensin II formation in humans . Eur Heart J 1995;16(suppl N):79-85.
131. [131] Lindpaintner K, Jin M, Niedermaier N, Wilhelm MJ, Ganten D. Cardiac angiotensinogen and its local activation in isolated perfused beating heart. Circ Res 1990;67:564-573.
132. [132] McConkey DJ, Orrenius S. The role of Ca2+ in the regulation of apoptosis. J Leukoc Biol 1996;59:775-783.
133. [133] Cigola E, Kajstura J, Li B, Meggs LG, Anversa P. Angiotensin II activates programmed cell death in vitro. Exp Cell Res 1997;231:363-371.
134. [134] Movsesian MA, Karimi M, Green K, Jones LR. Ca2+-transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium. Circulation 1994;90:653-657.
135. [135] Studer R, Reinecke H, Bilger J, et al. Gene expression of the cardiac Na+-Ca2+ exchanger in end-stage human heart failure. Circ Res 1994;75:443-453.
136. [136] Arai M, Alpert NR, Mac Lennan DH, Barton P, Periasamy M. Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 1993;72:463-469.
137. [137] Feldman AM, Ray PE, Silan CM, Mercer JA, Minobe W, Bristow MR. Selective gene expression in failing human heart. Quantification of steady state levels of messenger mR.N.A. in endomyocardial biopsies using the polymerase chain reaction. Circulation 1991;83:1866-1872.
138. [138] Böhm B, Reiger B, Schwinger RHG. cAMP concentrations, cAMP-dependent protein kinase activity, and phospholamban in non-failing and failing myocardium. Cardiovasc Res 1994;26:1713-1719.
139. [139] Ohta K, Kim S, Hamaguchi A, Miura K, Yukimura T, Iwao H. Expression of sarcoplasmic reticulum Ca2+-ATPase mRNA in the hypertrophied heart of young spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1995;22(Suppl 1):228-229.
140. [140] Levitsky D, de la Bastie D, Schwartz K, Lompré AM. Ca2+-ATPase and function of sarcoplasmic reticulum during cardiac hypertrophy. Am J Physiol 1991;261(Suppl.):23-26.
141. [141] Zarain-Herzberg A, Rupp H, Elimban V, Dhalla NS. Modification of sarcoplasmic gene expression in pressure overload cardiac hypertrophy by etomoxir. FASEB J 1996;10:1303-1309.
142. [142] Feldman AM, Weinberg EO, Ray PE, Lorell BH. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res 1993;73:184-192.
143. [143] Stein B, Bartel S, Kirchhefer U, et al. Relation between contractile function and regulatory cardiac proteins in hypertrophied hearts. Am J Physiol 1996;270:H2021-H2028.
144. [144] Zarain-Herzberg A, Afzal N, Elimban V, Dhalla NS. Decreased expression of cardiac sarcoplasmic reticulum Ca2+-pump ATPase in congestive heart failure due to myocardial infarction. Mol Cell Biochem 1996;163/164:285-290.